Transplantation in resource-limited setting: using HIV-positive donors for HIV-positive patients

Elmi Muller

Groote Schuur Hospital, University of Cape Town, South Africa

Abstract. Background: A HIV positive-to-positive program was started in South Africa in 2008. The program was started because dialysis is not freely available to everyone, but severely limited and only available to a selected group of patients. Patients and Methods: Between September 2008 and March 2015, 29 patients were transplanted from HIV-positive brain-dead donors at Groote Schuur Hospital transplant team. Donors were either naïve to anti-retroviral therapy or on first line therapy. The recipients were selected to have undetectable plasma HIV type 1 RNA levels and be on a stable antiretroviral regimen. CD4+ T-cell counts of at least 200/mm³ in last 6 months prior to transplant, with no previous serious opportunistic infections. Results: Survivors in the study were followed for a median of 2.4 years. The rate of patient survival was 84% at 1 year and 74% at 5 years. The corresponding graft survival rate was 93% and 84%. Conclusion: Using HIV-positive donors might resolve some of the problems we are experiencing in getting enough donors for our patients with ESRD. In the USA the HOPE act was accepted in 2014 and this might now also impact on the use of HIV positive donors elsewhere in the world.

Background

In 2008, when the HIV positive-to-positive program started, patients with ESRD and HIV would be turned down for dialysis. The reason was that they were seen as unfit for transplantation and therefore not suitable dialysis patients. This meant that anybody with HIV and ESRD was doomed to die. This situation remained unchallenged for a number of years, especially as the rollout of antiretroviral therapy was quite slow in the state sector.

The HIV population with ESRD started to grow dramatically in 2008 in South Africa. A major problem with having HIV is that a large percentage of these people will develop HIV-associated nephropathy (HIVAN). Histologically, HIVAN is a collapsing form of focal sclerosing glomerulosclerosis (FSGS), which can be distinguished from idiopathic FSGS by the presence of microcystic tubular dilatation and interstitial inflammation [1].

Modelling the incidence of ESRD and HIV in Sub Sahara Africa we know that we...
have at least 20.9 million people over the age of 15 years with HIV-related chronic kidney disease (CKD), according to UNAIDS prevalence statistics. It is estimated that ~ 60% of these people are treated with anti-retroviral therapy.

In South Africa we have a unique situation in view of the fact that we have low antiretroviral therapy resistance rates [6, 7, 8, 9]. Most patients who failed second-line ART in South Africa, have wild-type virus and resistance rates remain less than 5% in our HIV population. So in our setting the issues transplanting HIV-positive patients are mostly that they have very high rejection rates, that they need powerful and expensive immunosuppression as these patients have a dysregulated immunosystem rather than a suppressed one. They also have a high infection risk as opportunistic infections are more common in immunosuppressed and HIV-positive patients, and in Africa opportunistic infection remains a major reason why transplant patients might run into trouble [10].

**Problems with using HIV positive donors**

Concerns about a second viral strain remained a problem. In the literature the outcomes and reports of HIV-positive patients with super-infections are difficult to interpret as there are a lot of methodological difficulties which often yield conflicting results [4, 5]. When a patient with low viral load gets exposed to a second viral strain, a superinfecting strain may be detectable for only a short period of time. Viral fitness and the ability of a viral strain to replicate effectively in a given environment, may play a role to determine whether the two different strains will eventually become undetectable in standard resistance tests or whether outgrowth of a different virus from the baseline or whether a novel recombinant virus will become detectable [4].

**South African situation**

In South Africa we have a unique situation in view of the fact that we have low antiretroviral therapy resistance rates [6, 7, 8, 9]. Most patients who failed second-line ART in South Africa, have wild-type virus and resistance rates remain less than 5% in our HIV population. So in our setting the issues transplanting HIV-positive patients are mostly that they have very high rejection rates, that they need powerful and expensive immunosuppression as these patients have a dysregulated immunosystem rather than a suppressed one. They also have a high infection risk as opportunistic infections are more common in immunosuppressed and HIV-positive patients, and in Africa opportunistic infection remains a major reason why transplant patients might run into trouble [10].

**Exclusion and inclusion criteria**

The HIV positive-to-positive program in Cape Town is a deceased donor program where the donors are HIV positive and selected according to the following criteria:

- ART-naïve donor
- If on ART, must be on first line treatment with no resistance
- Normal serum creatinine
- No proteinuria
- Protocol biopsy on reperfusion of kidney

No donor with the following problems is used:

- Active viral/fungal/parasitic infection
- Malignancies
- Sepsis
- Possible HIVAN present

Recipients are selected to have undetectable plasma HIV type 1 RNA levels and be on a stable antiretroviral regimen. CD4+ T-cell counts of at least 200/mm³ in last 6 months prior to transplant, with no previous serious opportunistic infections. If a patient had previous tuberculosis infection, it must be fully treated.
Results

In the study we have enrolled 29 patients over the last 5 years. Five patients died after transplant. The reasons for death were myocardial infarction, lung squamous cell cancer, pancreatitis with a duodenal perforation, disseminated Aspergillosis and Klebsiella Pneumonia sepsis. Two patients lost their grafts in the 1st week after transplantation: 1 with venous thrombosis of the graft and 1 with acute severe rejection within 1 week after transplantation. A 3rd patient lost her graft with chronic vascular rejection and fibrosis of the graft 2 years after her transplant. The risk of rejection in this patient population group is higher than expected in HIV-negative patients. In the Cape Town study, rejection took place on 8 occasions in 5 of the patients, which gives an acute rejection rate of 18%. This happened despite induction therapy with thymoglobuline. A dysregulated immune response might be the reason for high rejection rates despite potent immunsuppression, and similar high rejection episodes were reported in the NIH study using HIV-negative donors for HIV-positive recipients [11].

Using HIV-positive donors might resolve some of the problems we are experiencing in getting enough donors for our patients with ESRD. In the USA, the HOPE act was accepted in 2014 and this might now also impact on the use of HIV-positive donors elsewhere in the world.

Conflict of interest

None.

References

[1] Laurinavicius A, Harwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int. 1999; 56: 2203-2213. CrossRef PubMed

[2] Okpechi I, Swanepoel C, Duffield M, Mahala B, Wearne N, Alaghe S, Barday Z, Arendse C, Rayner B. Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy database. Nephrol Dial Transplant. 2011; 26: 1853-1861. CrossRef PubMed

[3] Wearne N, Swanepoel CR, Boule A, Duffield MS, Rayner BL. The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations. Nephrol Dial Transplant. 2012; 27: 4109-4118. CrossRef PubMed

[4] Waters L, Smit E. HIV-1 superinfection. Curr Opin Infect Dis. 2012; 25: 42-50. CrossRef PubMed

[5] Strecker H, Li B, Poon AF, Schneidewind A, Glad-den AD, Power KA, Daskalakis D, Buzner S, Zaniga R, Brander C, Rosenberg ES, Frost SD, Altford M, Allen TM. Immune-driven recombination and loss of control after HIV superinfection. J Exp Med. 2008; 205: 1789-1796. CrossRef PubMed

[6] Jacobs GB, Laten A, van Rensburg EJ, Bodem J, Weissbrich B, Reithwil A, Preiser W, Engelbrecht S. Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naïve patients from Cape Town, South Africa. AIDS Res Hum Retroviruses. 2008; 24: 1009-1012. CrossRef PubMed

[7] Parboosing R, Naidoo A, Gordon M, Taylor M, Vella V. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol. 2011; 83: 1508-1513. CrossRef PubMed

[8] Nwobegahay JM, Bessong PO, Masebe TM, Mavhanda LG, Iveriebor BC, Selabe G. Prevalence of antiretroviral drug resistance mutations and HIV-1 subtypes among newly-diagnosed drug-naive persons visiting a voluntary testing and counselling centre in northeastern South Africa. J Health Popul Nutr. 2011; 29: 303-309. CrossRef PubMed

[9] Nwobegahay J, Selabe G, Ndjeka NO, Manhaeve C, Bessong PO. Low prevalence of transmitted genetic drug resistance in a cohort of HIV-infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa. J Med Virol. 2012; 84: 1839-1843. CrossRef PubMed

[10] Fenner L, Reid SE, Fox MP, Garone D, Welling-tom M, Prozesky H, Zwahlen M, Schomaker M, Wandeler G, Kancheya N, Boule A, Wood R, Hosnostra G, Egger M; IeDEA Southern Africa. Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. Trop Med Int Health. 2013; 18: 194-198. CrossRef PubMed

[11] Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subranaman A, Mills JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stabilein DM, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010; 363: 2004-2014. CrossRef PubMed